A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor.

ABSTRACT: Cancer immunotherapy has recently drawn remarkable attention as promising results in the clinic have shown its ability to improve the overall survival, and T cells are considered to be one of the primary effectors for cancer immunotherapy. Enhanced and restored T cell tumoricidal activity has shown great potential for killing cancer cells. Bispecific T cell engagers (TCEs) are a growing class of molecules that are designed to bind two different antigens on the surface of T cells and cancer cells to bring them in close proximity and selectively activate effector T cells to kill target cancer cells. New T cell engagers are being investigated for the treatment of solid tumors. The activity of newly developed T cell engagers showed a strong correlation with tumor target antigen expression. How

SUBMITTER: Ma H 

PROVIDER: S-EPMC7293198 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature